- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
- Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Yuba City, California • Centennial, Colorado + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- BAX69 + infusional 5-FU/LV, BAX69 + panitumumab, BAX69 + 5-FU/LV, Standard of Care, Standard of Care
- Biological · Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 12
- States / cities
- Port Saint Lucie, Florida • Joliet, Illinois • Goshen, Indiana + 9 more
- Conditions
- Metastatic Adenocarcinoma of the Colon or Rectum, Malignant Solid Tumors
- Interventions
- Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Sarasota, Florida • Houston, Texas + 1 more
- Conditions
- Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites
- Interventions
- BAX69 Single-Route Arm, BAX69 Double-Route Arm
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 6
- States / cities
- Miami, Florida • Augusta, Georgia • Silver Spring, Maryland + 3 more